BHCM
PRCT icon

Brevan Howard Capital Management’s Procept Biorobotics PRCT Stock Holding History

Brevan Howard Capital Management’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.55M Buy
68,723
+20,484
+42% +$513K 0.01% 843
2026
Q1 		$1.21M Buy
48,239
+20,357
+73% +$574K 0.01% 816
2025
Q4 		$877K Buy
27,882
+16,746
+150% +$555K 0.01% 826
2025
Q3 		$397K Buy
11,136
+4,074
+58% +$186K ﹤0.01% 1404
2025
Q2 		$407K Buy
+7,062
New +$399K ﹤0.01% 1437
2025
Q1 		– Sell
-28,849
Closed -$2.32M – 1394
2024
Q4 		$2.32M Buy
28,849
+22,094
+327% +$1.89M 0.01% 266
2024
Q3 		$541K Buy
+6,755
New +$480K ﹤0.01% 659

Other funds holding PRCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Brevan Howard Capital Management's PRCT Position: Q2 2026 in Review

Brevan Howard Capital Management increased its Procept Biorobotics (PRCT) stake by 42% in Q2 2026, buying an estimated $513K and bringing the position to 68,723 shares worth $1.55M. The position accounts for 0.01% of the portfolio, ranked #843.

Brevan Howard Capital Management first reported a position in PRCT in Q3 2024 and has held it in 7 quarters since. The position peaked at $2.32M in Q4 2024. 253 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

  • Brevan Howard Capital Management held 68,723 shares of Procept Biorobotics worth $1.55M as of Q2 2026.
  • Brevan Howard Capital Management bought 20,484 Procept Biorobotics shares in Q2 2026, an estimated $513K.
  • Procept Biorobotics made up 0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #843 holding.
  • Brevan Howard Capital Management first reported a position in Procept Biorobotics in Q3 2024 and has held it in 7 quarters since.
  • Brevan Howard Capital Management's Procept Biorobotics position peaked at $2.32M in Q4 2024.
  • 253 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.